<DOC>
	<DOCNO>NCT00877110</DOCNO>
	<brief_summary>Funding Source - FDA OOPD FDR004128 The goal study see safe feasible give chemotherapy , natural killer ( NK ) cell , antibody call 3F8 . The NK cell must come family member share half HLA proteins immune protein important transplant . NK cell type white blood cell . They recognize kill abnormal cell body work together antibody kill target cell . The antibody 3F8 specifically recognize protein present target cancer cell .</brief_summary>
	<brief_title>Anti-GD2 3F8 Antibody Allogeneic Natural Killer Cells High-Risk Neuroblastoma</brief_title>
	<detailed_description />
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Diagnosis NB define international criterion , i.e. , histopathology ( confirm MSKCC Department Pathology ) bone marrow metastases plus high urine catecholamine level Highrisk NB define riskrelated treatment guideline International NB Staging System,57 i.e. , stage 4 ( age ) without ( &gt; 365 day age ) MYCN amplification , MYCNamplified stage 3 ( unresectable ; age ) , MYCNamplified stage 4S . Patients must history tumor progression persistent disease failure achieve complete response follow standard therapy . Patients must evaluable ( microscopic marrow metastasis , elevate tumor marker , positive MIBG PET scan ) measurable ( CT , MRI ) disease document completion prior systemic therapy . Disease stag approximately within one month treatment . Human antimouse antibody ( HAMA ) titer &lt; 1000 Elisa units/ml applicable Available autologous stem cell : â‰¥2 x 106 CD34+ cells/kg Adequate cardiac function measure echocardiogram Eligible NK donor Signed informed consent indicate awareness investigational nature program . Donor Eligibility Donor bloodrelated HLAhaploidentical recipient . Donor undergone serologic test transmissible disease per blood banking guideline organ tissue donor . Tests include limited : HepBsAg , HepBsAb , HepBcAb , HepC antibody , HIV , HTLV I II , VZV , CMV VDRL , West Nile Virus Chagas screen . Donor must normal negative test result HIV , HTLV I II , West Nile Virus . Donor exposure viral pathogen discuss casebycase basis investigator . Donor must able undergo leukopheresis total volume 1015 liter . There age restriction donor . Patients CR/VGPR disease Existing severe major organ dysfunction , i.e. , renal , cardiac , hepatic , neurologic , pulmonary , gastrointestinal toxicity &gt; = grade 3 except hear loss , alopecia , anorexia , nausea , hyperbilirubinemia hypomagnesemia TPN , may grade 3 ANC &gt; 500/uL ; platelet count &gt; 25K/uL . History allergy mouse protein Active lifethreatening infection HAMA titer &gt; 1000 Elisa units/ml Inability comply protocol requirement Donor Exclusion Criteria Cardiac risk factor preclude ability undergo leukopheresis Concurrent malignancy autoimmune disease Donor pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>BETA-D-GLUCAN</keyword>
	<keyword>CYCLOPHOSPHAMIDE ( CYTOXAN )</keyword>
	<keyword>MAB 131 I - 3F8</keyword>
	<keyword>TOPOTECAN</keyword>
	<keyword>VINCRISTINE</keyword>
	<keyword>Neuroblastoma</keyword>
	<keyword>09-011</keyword>
</DOC>